Lung Surfactant for Pulmonary Barrier Restoration in Patients With COVID-19 Pneumonia

Ursula Mirastschijski, Rolf Dembinski, Kathrin Maedler, Ursula Mirastschijski, Rolf Dembinski, Kathrin Maedler

No abstract available

Keywords: ARDS; COVID-19; SARS-CoV-2; inflammation; lung surfactant; pneumonia.

Figures

Figure 1
Figure 1
Model of lung and alveolar morphology. Lung surfactant is produced by type-II-alveolar cells. Created using smart servier medical art under https://creativecommons.org/licenses/by/3.0/.
Figure 2
Figure 2
Hypothetical mechanism of externally applied lung surfactant for pulmonary protection in severe COVID-19 associated ARDS. COVID-19 associated ARDS is characterized by massive macrophage infiltration, tissue alveolar macrophage activation and a potentiation of cytokine production in the lung (cytokine “storm”), which leads to the destruction of surfactant producing type II alveolar cells, which worsens the situation through the loss of anti-inflammatory, anti-fibrotic lung surfactant. Exogenous surfactant may reduce inflammation and thus restore pulmonary survival. Created using smart servier medical art under https://creativecommons.org/licenses/by/3.0/.

References

    1. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. . A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. (2020) 382:1787–99. 10.1056/NEJMoa2001282
    1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. (2020) 579:270–3. 10.1038/s41586-020-2012-7
    1. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. . SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. (2020) 181:271–80.e8. 10.1016/j.cell.2020.02.052
    1. Mason RJ. Biology of alveolar type II cells. Respirology. (2006) 11(Suppl.):S12–5. 10.1111/j.1440-1843.2006.00800.x
    1. Alcorn JL. Pulmonary surfactant trafficking and homeostasis. In: Sidhaye VK, Koval M. editors. Lung Epithelial Biology in the Pathogenesis of Pulmonary Disease. Philadelphia, PA: Elsevier Academic Press; (2017). p. 59–75. 10.1016/B978-0-12-803809-3.00004-X
    1. Gurka DP, Balk RA. Acute respiratory failure. In: Parrillo JE, Dellinger RP. editors. Critical Care Medicine. Principles of Diagnosis and Management in the Adult. Philadelphia, PA: Mosby Elsevier; (2008). p. 773–94. 10.1016/B978-032304841-5.50040-6
    1. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. (2020) 8:e21. 10.1016/S2213-2600(20)30116-8
    1. Daniels CB, Orgeig S. Pulmonary surfactant: the key to the evolution of air breathing. News Physiol Sci. (2003) 18:151–7. 10.1152/nips.01438.2003
    1. Bernhard W. Lung surfactant: function and composition in the context of development and respiratory physiology. Ann Anat. (2016) 208:146–50. 10.1016/j.aanat.2016.08.003
    1. Wright JR. The “wisdom” of lung surfactant: balancing host defense and surface tension-reducing functions. Am J Physiol Lung Cell Mol Physiol. (2006) 291:L847–50. 10.1152/ajplung.00261.2006
    1. Schicht M, Garreis F, Hartjen N, Beileke S, Jacobi C, Sahin A, et al. . SFTA3 - a novel surfactant protein of the ocular surface and its role in corneal wound healing and tear film surface tension. Sci Rep. (2018) 8:9791. 10.1038/s41598-018-28005-9
    1. Tschernig T, Veith NT, Diler E, Bischoff M, Meier C, Schicht M. The importance of surfactant proteins-new aspects on macrophage phagocytosis. Ann Anat. (2016) 208:142–5. 10.1016/j.aanat.2016.07.005
    1. Mittal RA, Hammel M, Schwarz J, Heschl KM, Bretschneider N, Flemmer AW, et al. . SFTA2–a novel secretory peptide highly expressed in the lung–is modulated by lipopolysaccharide but not hyperoxia. PLoS ONE. (2012) 7:e40011. 10.1371/journal.pone.0040011
    1. Diler E, Schicht M, Rabung A, Tschernig T, Meier C, Rausch F, et al. . The novel surfactant protein SP-H enhances the phagocytosis efficiency of macrophage-like cell lines U937 and MH-S. BMC Res Notes. (2014) 7:851. 10.1186/1756-0500-7-851
    1. Ramanathan R. Surfactant therapy in preterm infants with respiratory distress syndrome and in near-term or term newborns with acute RDS. J Perinatol. (2006) 26(Suppl. 1):S51–6; discussion S63-4. 10.1038/sj.jp.7211474
    1. Been JV, Zimmermann LJ. What's new in surfactant? A clinical view on recent developments in neonatology and paediatrics. Europ J Pediatrics. (2007) 166:889–99. 10.1007/s00431-007-0501-4
    1. Ainsworth SB, Beresford MW, Milligan DW, Shaw NJ, Matthews JN, Fenton AC, et al. . Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks' gestation: a randomised trial. Lancet. (2000) 355:1387–92. 10.1016/S0140-6736(00)02136-X
    1. Spragg RG, Lewis JF, Walmrath HD, Johannigman J, Bellingan G, Laterre PF, et al. . Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med. (2004) 351:884–92. 10.1056/NEJMoa033181
    1. Mirastschijski U, Schwab I, Coger V, Zier U, Rianna C, He W, et al. . Lung surfactant accelerates skin wound healing: a translational study with a randomized clinical Phase I study. Sci Rep. (2020) 10:2581. 10.1038/s41598-020-59394-5
    1. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. . COVID-19 infection: the perspectives on immune responses. Cell Death Differ. (2020) 27:1451–4. 10.1038/s41418-020-0530-3
    1. Findlay RD, Taeusch HW, Walther FJ. Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics. (1996) 97:48–52.
    1. Yao XH, Li TY, He ZC, Ping YF, Liu HW, Yu SC, et al. . [A pathological report of three COVID-19 cases by minimally invasive autopsies]. Zhonghua Bing Li Xue Za Zhi. (2020) 49:E009. 10.3760/cma.j.cn112151-20200312-00193

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner